The metabolism of ceramides is deregulated in the brain of Alzheimer’s disease (AD) patients and is associated with apolipoprotein (APO) APOE4 and amyloid-β pathology. This evidence concerns the gene AOPEP and early-onset autosomal dominant Alzheimer disease.